Table 2.

Recommendations regarding in-hospital prophylaxis.

International Societies and Consensus Groups	Recommendations
ISTH	•Thromboprophylaxis with LMWH or UFH in all hospitalised patients, unless contraindicated •Intermediate dose of LMWH in high-risk patients •50% dose increase in obese patients
Global COVID-19 Thrombosis Collaborative Group	•PE risk stratification in all hospitalised patients •Thromboprophylaxis with LMWH or UFH in hospitalised critically ill patients and those at high risk of PE, unless contraindicated •NOACs could be used in the prehospitalisation period in high risk patients
ESC	•Thromboprophylaxis at standard prophylactic dose in all hospitalised patients, unless contraindicated
WHO	•Thromboprophylaxis with LMWH or UFH in all hospitalised patients, unless contraindicated
CHEST Guideline and Expert Panel Report	•Thromboprophylaxis at standard dose in all hospitalised patients, unless contraindicated •LMWH and fondaparinux over UFH to limit staff exposure
NIH	•Thromboprophylaxis with LMWH or UFH in all hospitalised patients, unless contraindicated
Expert Opinion of the Section on Pulmonary Circulation of PCS	•PE risk stratification in all hospitalised patients •Thromboprophylaxis in hospitalised critically ill patients and those at high risk of PE, unless contraindicated •UFH in patients with CKD stage 4 or 5 •Intermediate LMWH dose at high-risk patients •If HIT is suspected, bivalirudin over fondaparinux should be used •If bivalirudin is unavailable, fondaparinux might be considered
SISET position paper	•Thromboprophylaxis with LMWH, UFH, or fondaparinux in all hospitalised patients, unless contraindicated •Intermediate dose of LMWH in patients with multiple risk factors (BMI >30, previous VTE, active cancer, etc.)
SSH Working Party on Hemostasis	•Thromboprophylaxis in all hospitalised patients, unless contraindicated •In patients with a creatinine clearance >30 mL/min, LMWH should be administered •In patients with a creatinine clearance <30 mL/min, UFH SC two or three times daily or IV should be administered •Increased dose of LMWH or UFH in patients >100 kg •No use of NOACs •Intermediate or therapeutic dose of LMWH or UHF in ICU patients with a large increase in D-dimer, severe inflammation, signs of hepatic or renal dysfunction, or imminent respiratory failure

Abbreviations: ISTH, International Society on Thrombosis and Haemostasis; LMWH, low-molecular-weight heparin; UFH, unfractionated heparin; COVID-19, coronavirus-19 disease; PE, pulmonary embolism; NOAC, novel oral anticoagulant; ESC, European Society of Cardiology; WHO, World Health Organization; CHEST, American College of Chest Physicians; NIH, National Institutes of Health; PCS, Polish Cardiac Society; CKD, chronic kidney disease; HIT, heparin-induced thrombocytopaenia; SISET, Italian Society on Thrombosis and Haemostasis; BMI, body mass index; VTE, venous thromboembolism; SSH, Swiss Society of Hematology; SC, subcutaneous; IV, intravenous.